Advances with pharmacotherapy for peritoneal metastasis

References

• Chu DZ, Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer. 1989;63(2):364–367.
   PubMed Web of Science ®Google Scholar
• Sugarbaker PH. Building on a consensus. J Surg Oncol. 2008;98(4):215–216.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Endou Y, et al. Peritoneal cancer treatment. Expert Opin Pharmacother. 2014;15(5):623–636.
   PubMed Web of Science ®Google Scholar
• Verwaal VJ, Bruin A, Boot H, et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2633–2635.
   PubMed Web of Science ®Google Scholar
• O’Dwyer S, Verwaal VJ, Sugarbaker PH. Evolution of treatment for peritoneal metastasis from colorectal cancer. J Clin Oncol. 2015;33(18):2122–2123.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE). Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. IPG 331, ( access 13 August 2013), http://ww.nice.org.uk/guidance/IPG331
   Google Scholar
• Quadros CA, Laporte GA, Huguenin JFL. Latin American Regustry of Peritoneal Diseases-LARPD participates. Current practice of Latin American centers in the treatment of peritoneal diseases with cytoreductive surgery with HIPEC. Eur J Surg Oncol. 2018;44(11):1800–1804. Epub 2018 Jul 11.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27(8):1385–1442. Epub 2016 Jul5.
   Web of Science ®Google Scholar
• National Comprehensive Cancer Network, NCCN Guidelines Version 1.2019, Colon Cancer, MS 27-30,
   Google Scholar
• Yonemura Y, Endou Y, Bando E, et al. The usefulness of oral TS-1 treatment for potentially curable gastric cancer patients with intraperitoneal free cancer cells. Cancer Ther. 2006;4:135–142.
   Google Scholar
• Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. European Journal of Surgical Oncology (EJSO). 2013;40(1):12–26.
   PubMed Web of Science ®Google Scholar
• Coccolini F, Catena F, Glehen O, et al. Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systemic review and meta-analysis. European Journal of Surgical Oncology (EJSO). 2015;41(7):911–919.
   PubMed Web of Science ®Google Scholar
• Baron MA. Structure of intestinal peritoneum in man. Am J Anat. 1941;169:429–497.
   Google Scholar
• Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: A pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2011;30(3): 263–267.
   PubMed Web of Science ®Google Scholar
• Hong SH, Shin YR, Roh Y, et al. Treatment outcomes of systemic chemotherapy for peritoneal carcinomatosis arising from gastric cancer with no measurable disease: retrospective analysis from a single center. Gastric Cancer. 2013;16(3):290–300.
   PubMed Web of Science ®Google Scholar
• Wilke H, Muro K, Van Custem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric cancer or gastro-esophageal junction adenocarcinoma (RAINBOW): a double-blind, randomized phase 3 trial. Lancet Oncol. 2014;15(11):1224–1235.
   PubMed Web of Science ®Google Scholar
• Nishina T, Boku N, Gotoh M, et al. Gastrointestinal oncology study group of the japan clinical oncology group. Randomized phase II study of second line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG407). Gastric Cancer. 2016;19(3):902–910.
   PubMed Web of Science ®Google Scholar
• Alexander HR, Burlk AP. Diagnosis and management of patients with malignant peritoneal mesothelioma. J Gastrointest Oncol. 2016;7(1):79–86.
   PubMed Web of Science ®Google Scholar
• Sakurai H, Komine K, Ishioka C. Efficacy of modified FOLFOX6 chemotherapyfor patients with unresectable pseudimyxoma peritonei. Int J Clin Oncol., 2020;25:774-781.
   Google Scholar
• de Bree E, Rovers KP, Stamatiou D, et al. The evolving management of small bowel adenocarcinoma. Acta Oncol . 2018;57(6):712–722. Epub 2018 Jan 30.
   PubMed Web of Science ®Google Scholar
• Los G, Mutsaers PHA, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: A comparison with systemic chemotherapy. Cancer Res. 1989;49(12):3380–3384.
   PubMed Web of Science ®Google Scholar
• de Bree E, Tsiftsis DD. Principles of Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis. In: Gonzalez-Moleno S, editor. Advances in peritoneal surface oncology. Springer; 2007. p. 39-51. doi: 10.1007/978-3-540-30760-0_4.
   Google Scholar
• Fushida S, Kinoshita J, Kaji M, et al. Phase I/II study of intraperitoneal docetaxel plus S-1 for the gastric cancer patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2013;71(5):1265–1272.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin penetration in murine ovarian cancer. Cancer Res. 1979;43:3209–3214.
   Google Scholar
• Van der S. A pharmacokinetics and pharmacodynamic rationale for perioperative cancer chemotherapy in patients with peritoneal carcinomatosis. Uppsala: Acta Universitasis Upsaliensis;2010. pp37–75. ASSN 1651-6206.
   Google Scholar
• Yonemura Y, Canbay E, Sako S, et al. Pharmacokinetics of docetaxel during hyperthermic intraperitoneal chemotherapy for peritoneal metastasis. Jpn J Cancer Chemother. 2014;41:2496–2499.
   PubMedGoogle Scholar
• Van der Speeten K, Stuart OA, Chang D, et al. Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis. Cancer Chemother Pharmacol. 2011;63:247–256.
   Google Scholar
• Van der Speeten K, Stuart OA, Mahteme H, et al. Pharmacology of perioperative 5-fluorouracil. J Surg Oncol. 2010;102(7):730–735.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Bandou E, Sawa T, et al. A new treatment by neoadjuvant intraperitoneal-systemic chemotherapy and peritonectomy for peritoneal dissemination from gastric cancer. Euro J Surg Oncol. 2006;32(6):661–665.
   PubMed Web of Science ®Google Scholar
• Dudrick RL, Flessner MF. Pharmacokinetic problems in peritoneal drug administration: tissue penetration and surface exposure. JNCI. 1997;89(7):480–487.
   PubMedGoogle Scholar
• Bhatt A, Yonemura Y, Benzerdjeb N, et al. Pathological assessment of cytoreductive surgery specimens and its unexplored prognostic potential-a prospective multi-centric study. Eur J Surg Oncol. 2019;45(12):2398–2404.
   PubMed Web of Science ®Google Scholar
• Imano M, Imamoto H, Itoh T, et al. Impact of intraperitoneal chemotherapy after gastrectomy with positive cytological findings in peritoneal washings. Eur Surg Res. 2011;47(4):254–259.
   PubMed Web of Science ®Google Scholar
• Urano M, Ling CC. Thermal enhancement of melphalan and oxaliplatin cytotoxicity in nitro. Int J Hyperthermia. 2002;18(4):307–315.
   PubMed Web of Science ®Google Scholar
• Barlogie B, Corry PM, Drewinko B. In vitro thermochemotherapy of human colon cancer cells with CDDP and Mitomycin C. Cancer Res. 1980;40(4):1165–1168.
   PubMed Web of Science ®Google Scholar
• Lepock JR. How do cells respond to their thermal environment? Int J Hyperthermia. 2005;21(8):681–687.
   PubMed Web of Science ®Google Scholar
• Bijelic L, Sugarbaker PH, Stuart OA. Hyperthermic intraperitoneal chemotherapy with melphalan. Gastroenterol Res Prac. 2012, Article ID827534. ;5 pages. doi: 10.1155/2012/827534.
   Web of Science ®Google Scholar
• Sugarbaker PH, Van der Speeten K, Stuart OA, et al. Impact of surgical and clinical factors on the pharmacology of intraperitoneal doxorubicin in 145 patients with peritoneal carcinomatosis. Eur J Surg Oncol. 2011;37(8):719–726.
   PubMed Web of Science ®Google Scholar
• Rowinsky MD, Elic K. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann Rev Med. 1997;48(1):353–374.
   PubMed Web of Science ®Google Scholar
• Van Zuylen L, Verweij I, Sparreboom A. Role of formulation vehicles in taxane pharmacology. Invest New Drugs. 2001;19(2):125–141.
   PubMed Web of Science ®Google Scholar
• Woodcock DM, Linsenmeyer ME, chojunowski G, et al. Reversal of multidrug resistance by surfactants. Br J Cancer. 1992;66(1):62–68.
   PubMed Web of Science ®Google Scholar
• Miyamoto K, Shimada T, Sawamoto K, et al. Disposition kinetics of Taxanes in peritoneal dissemination. Gastroenterol Res Pract. 2012;9 pages. Article ID963403. doi:10.1155/2012/963403
   Web of Science ®Google Scholar
• Mohamed F, Marchettini P, Stuart A, et al. Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol. 2003;10(4):463–468.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Sako S, et al. Pharmacokinetics of docetaxel during hyperthermic intraperitoneal chemotherapy for peritoneal metastasis. Gan To Kagakuryoho. 2014;41:2496–2499.
   PubMedGoogle Scholar
• Yonemura Y, Sako S, Wakama S, et al. History of peritoneal surface malignancy treatment in Japan. Indian J Surg Oncol . 2019;10(S1):3–11. Epub 2019 Feb 19.
   PubMed Web of Science ®Google Scholar
• Jayne D. Ceelen WP. Molecular biology of peritoneal carcinomatosis. Cancer treatment and research. Ahmedabad: Springer; 2007. 21–31.
   Google Scholar
• Yonemura Y, Canbay E, Liu Y, et al. Trans-lymphatic metastasis in peritoneal dissemination. J Gastroint Dig Syst. 2013;S12. DOI:10.4172/2161-069X.S12-007.
   Google Scholar
• Sugarbaker PH. Observation concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Peritoneal carcinomatosis: a multidisciplinary approach. Sugarbaker PH, Edited by. Boston, Dordrecht, London: Kluwar Academic Publisher; 1997. p. 79–100.
   Google Scholar
• Tsujimoto H, Takahashi T, Hagiwara A, et al. Site-specific implantation in the milky spots of malignant cells in peritoneal dissemination: immunohistochemical observation in mice inoculated intraperitoneally with bromodeoxyuridine-labeled cells. Br J Cancer. 1995;71(3):468–472.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Canbay E, Sako S, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy on lymph node metastasis from advanced gastric cancer with peritoneal metastasis. J Surg. 2019;11:1214.
   Google Scholar
• Hao Y, Liu Y, Ishibashi H, et al. Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis. Eur J Surg Oncol. 2019;45(8):1493–1497.
   PubMed Web of Science ®Google Scholar
• Marmor RA, Kelly KJ, Lowy AM, et al. Laparoscopy is safe and accurate to evaluate peritoneal surface metastasis prior to cytoreductive surgery. Ann Surg Oncol. 2015;23(5):1461–1467.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ishibashi H, Hirano M, et al. Effects of neoadjuvant laparoscopic hyperthermic intraperitoneal chemotherapy and neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastases from gastric cancer. Ann Surg Oncol . 2017;24(2):478–485. Epub 2016 Aug.
   PubMed Web of Science ®Google Scholar
• Bengtsson G, Carlsson G, Hafstrom L, et al. Natural history if patients with untreated liver metastasis from colorectal cancer. Am J Surg. 1981;141(5):586–589.
   PubMed Web of Science ®Google Scholar
• Sedeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer. 2000;88(2):358–363.
   PubMed Web of Science ®Google Scholar
• Koppe MJ, Boerman OC, Oyen WJ, et al. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg. 2006;243(2):212–222.
   PubMed Web of Science ®Google Scholar
• Jayne DG, Fool S, Loi C, et al. Peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2002;89(12):1545–1550.
   PubMed Web of Science ®Google Scholar
• Elias D, Blot F, El Otmany A, et al. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer. 2001;92(1):71–76.
   PubMed Web of Science ®Google Scholar
• Elias D, Lefevre JH, Chevalier J, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;20:6237–6242. Epub 2009 Nov 16.
   Google Scholar
• Yonemura Y, Takao N, Ichinose M, et al. Treatment failure following complete cytoreductive surgery for peritoneal metastasis from colorectal cancer. Gan To Kagakuryoho. 2016;43:1435–1439.
   PubMedGoogle Scholar
• Quenet F, Elias D, Roca L, et al. A unicancer phase III trial of hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis. Progige 7-ACCORD 15 trial. NCT00769405, N EudraCT: 2006-006175-20. 2018 ASCO Annual meeting;  Chicago. http://clicktoeditURL.com
   Google Scholar
• Rovers KP, de Bree E, Yonemura Y, et al. Treatment of peritoneal metastases from small bowel adenocarcinoma. Int J Hyperthermia. 2017;33(5):571–578.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yonemura Y, Levine EA, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastasis from a small bowel adenocarcinoma: multiinstitutional experience. Ann Surg Oncol. 2018;25(5):1184–1192.
   PubMed Web of Science ®Google Scholar
• Yan TD, Black D, Sugarbaker PH, et al. A systemic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer. Ann Surg Oncol. 2007;14(10):2702–2713.
   PubMed Web of Science ®Google Scholar
• Ji ZH, Peng KW, Yu Y, et al. Current status and future prospects of clinical trials on CRS+HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–570.
   PubMed Web of Science ®Google Scholar
• Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer A muti-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–2377.
   PubMed Web of Science ®Google Scholar
• Yonemura Y, Ishibashi H, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy on peritoneal metastasis from gastric cancer. World J of Pharmaceutical Med Res. 2019;5:19–23, 2455-3301
   Google Scholar
• Yang XJ, Huang CQ, Suo T, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy improves survival of patients with peritoneal carcinomatosis from gastric cancer: final results of a phase III randomized clinical trial. Ann Surg Oncol. 2011;18(6):1575–1581.
   PubMed Web of Science ®Google Scholar
• Carbone M, Adusumilli PS, Alexander HR Jr, et al. Mesothelioma: scientific clues for prevention, diagnosis, and therapy. CA Cancer J Clin. 2019;69(5):402–429. Epub 2019 Jul 8.
   PubMed Web of Science ®Google Scholar
• Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant mesothelioma: multi-institutional experiences. J Clin Oncol. 2009;20(36):6237–6242.
   Web of Science ®Google Scholar
• Chua TC, Yan TD, Smigielski ME, et al. Long-term survival in patients with pseudomyxoma peritonei treated with cytoreductive surgery and perioperative intraperitoneal chemotherapy: 10 years of experience from a single institution. Ann Surg Oncol. 2009;16(7):1903–1911. Epub 2009 Apr 23.
   PubMed Web of Science ®Google Scholar
• Chua TC, Moran BJ, Sugarbaker PH, et al. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–2456. Epub 2012 May 21.
   PubMed Web of Science ®Google Scholar
• Yonemura Y. Comprehensive treatment for peritoneal surface malignancy with an intent of cure. NPO to support peritoneal surface malignancy treatment; 2019. p. 17–24.
   Google Scholar
• van Driel WJ, Koole SM, Sikorska K, et al. Hyperthermic intraperitoneal chemotherapy in ovarian cancer. N Engl J Med. 2018 Jan 18;378(3):230–240.
   PubMed Web of Science ®Google Scholar
• Leebmann H, Piso P. PIPAC and HIPEC-competing or supplementary therapeutic procedures for peritoneal metastases. Chirurg. 2018;89:693–698.
   Google Scholar
• Thadi A, Khalili M, Morano WF, et al. Early investigations and recent advances in intraperitoneal immunotherapy for peritoneal metastasis. Vaccines (Basel). 2018 Sep;6(3):54. Published online 2018 Aug 10.
   Web of Science ®Google Scholar